BiotechTube

DOR/3TC/TDF

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hiv

Conditions

Hiv, Weight Gain

Trial Timeline

Apr 26, 2021 → Mar 31, 2024

NCT ID
NCT04665375

About DOR/3TC/TDF

DOR/3TC/TDF is a approved stage product being developed by Merck for Hiv. The current trial status is terminated. This product is registered under clinical trial identifier NCT04665375. Target conditions include Hiv, Weight Gain.

What happened to similar drugs?

20 of 20 similar drugs in Hiv were approved

Approved (20) Terminated (0) Active (0)
✅Generic HAART Triomune : d4T, 3TC, NVP + Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABVCiplaApproved
✅Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableAbbVieApproved
✅Lopinavir/RitonavirAbbVieApproved
✅Ritonavir boosted Atazanavir + Raltegravir + TDF/FTC (or 3TC)MerckApproved
✅RaltegravirMerckApproved
✅raltegravirMerckApproved
✅Kaletra + Isentress + Pre-study antiretroviral regimenMerckApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04665375ApprovedTerminated

Competing Products

20 competing products in Hiv

See all competitors
ProductCompanyStageHype Score
DOR/ISLMerckPhase 2
35
Dolutegravir 50 mg twice daily + Dolutegravir placebo twice dailyShionogiPhase 3
40
GSK1265744 10 mg oral solution + GSK1265744 5 mg tablet + GSK1265744 5 mg tabletShionogiPhase 1
29
GW810781ShionogiPhase 2
35
Generic HAART Triomune : d4T, 3TC, NVP + Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABVCiplaApproved
43
Antiretroviral Therapy (ART) + Baricitinib (LY3009104) 2 mgEli LillyPhase 2
42
Epoetin alfaJohnson & JohnsonPre-clinical
26
LevofloxacinJohnson & JohnsonPhase 1
29
SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；PlaceboJiangsu Hengrui MedicinePhase 1
29
ABBV-181 + PlaceboAbbViePhase 1
29
ABBV-382 + ABBV-382 + Placebo for ABBV-382AbbViePhase 1
29
Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableAbbVieApproved
43
lopinavir/ritonavir + lamivudineAbbViePre-clinical
26
Lopinavir/RitonavirAbbVieApproved
43
Budigalimab + Placebo + Budigalimab + PlaceboAbbViePhase 1
29
Budigalimab + Placebo for Budigalimab + ABBV-382 + Placebo for ABBV-382 + BudigalimabAbbViePhase 2
27
CVC 150 mg + CVC 300 mgAbbViePhase 2
35
Rosuvastatin 10 mg. daily for 96 weeks + PlaceboAstraZenecaPhase 2
35
Raltegravir + Placebo + Current ARTMerckPhase 3
40
Indinavir sulfate + Lamivudine + ZidovudineMerckPhase 3
40